EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio

Whats Happening:

EQT Life Sciences, through its LSP 7 fund, has co-led a $135 million Series B financing round for SpliceBio, a Spanish biotech company. The funding will support the Phase 1/2 clinical development of SpliceBio's lead gene therapy candidate, SB-007, for Stargardt disease, as well as advance the company's pipeline targeting indications in ophthalmology, neurology, and other therapeutic areas.

Key Moves:

• EQT Life Sciences co-leads $135 million Series B financing for SpliceBio

• Funding to support Phase 1/2 clinical trial of SB-007 for Stargardt disease

• Investment will advance SpliceBio's pipeline in ophthalmology, neurology, and other areas

By The Numbers:

• Series B financing round: $135 million

• Stargardt disease affects 1 in 8,000-10,000 people

• Over 1,200 known mutations cause Stargardt disease

Key Quotes:

• "This financing marks a pivotal milestone for SpliceBio as we advance the clinical development of SB-007 for Stargardt disease and continue to expand our pipeline across ophthalmology, neurology, and beyond," - Miquel Vila-Perelló, CEO and Co-Founder of SpliceBio

• "We are proud to support SpliceBio, a pioneer among the next generation of genetic medicine companies. Its Protein Splicing platform offers a novel solution to deliver large genes, one of the field's most pressing challenges," - Daniela Begolo, Managing Director at EQT Life Sciences

Bottom Line:

EQT Life Sciences' investment in SpliceBio represents a significant boost for innovative gene therapy approaches. The funding not only supports the development of a potential treatment for Stargardt disease but also demonstrates confidence in SpliceBio's Protein Splicing platform, which could have broader applications in addressing genetic disorders with large genes.

Read Full Article